Personalized cell-based therapy in ophthalmology: the cytokine profile of autologous cell products

S Je Avetisov , A M Subbot , A I Antohin , E A Kasparova , A A Kasparov , A S Pavljuk

Genes & Cells ›› 2012, Vol. 7 ›› Issue (1) : 49 -53.

PDF
Genes & Cells ›› 2012, Vol. 7 ›› Issue (1) : 49 -53. DOI: 10.23868/gc121683
Articles
other

Personalized cell-based therapy in ophthalmology: the cytokine profile of autologous cell products

Author information +
History +
PDF

Abstract

The content of the main pro- and anti- inflammatory cytokinesand growth factors in autologous cell products, designedfor personalized cell-based therapy in corneal endotheliumlesions was studied. It was established that cell productcontains substances that mediate the effectiveness of celltherapy. The influence of processing conditions on the concentrationof cytokines and growth factors in cell products isclarified. It is established that cytokine profile of the cell productis composed of pre-existing substances in freshly bloodserum and plasma (TGF-β1, TGF-β2, b-FGF, PDGF-AB, VEGF,IL-4, IF-γ) and those concentration of which increased as aresult of processing the cell product - incubation for 4 hoursat 37°C (IL-8) and stimulation with polyA:U (IL-1, 6, IF-α andTNF-α). The evaluation of cytokine profile of cell preparationreveals implementation mechanisms of therapeutic effect ofpersonalized cell-based therapy.

Cite this article

Download citation ▾
S Je Avetisov, A M Subbot, A I Antohin, E A Kasparova, A A Kasparov, A S Pavljuk. Personalized cell-based therapy in ophthalmology: the cytokine profile of autologous cell products. Genes & Cells, 2012, 7(1): 49-53 DOI:10.23868/gc121683

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Аветисов С.Э., Суббот А.М., Антохин А.И. и др. Персонализи- рованная клеточная терапия в офтальмологии I. Метод получения и цитофенотип аутологичного клеточного продукта. Клеточная транс- плантология и тканевая инженерия 2011; 6(2): 38-42.

[2]

Каспаров А.А. Офтальмогерпес. М.; 1994.

[3]

Каcпарова Е.А., Суббот А.М., Антохин А.И. и др. Клиниче- ская эффективность персонализированной клеточной терапии заболеваний эндотелия роговицы. Катарактальная и рефракционная хирургия 2011; 11(2): 45-9.

[4]

Gnecchi M., Zhang Z., Ni A. et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008; 103(11): 1204-19.

[5]

Maltais S., Tremblay J.P., Perrault L.P. et al. The paracrine effect: pivotal mechanism in cell-based cardiac repair. J. Cardiovasc. Transl. Res. 2010; 3(6): 652-62.

[6]

Patel S.A., Rameshwar P. Stem cell transplantation for hematological malignancies: prospects for personalized medicine and co-therapy with mesenchymal stem cells. Current. Pharmacogen. Personal. Med. 2011; 9(3): 229-39.

[7]

Horwitz E.M., Prather W.R. Cytokines as the major mechanism of mesenchymal stem cell clinical activity: expanding the spectrum of cell therapy. Isr. Med. Assoc. 2009. 11(4): 209-11.

[8]

Loffredo F.S., Steinhauser M.L., Gannon J. et al. Bone marrowderived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011; 8(4): 389-98.

[9]

Song S.-Y., Chung H.-M., Sung J.-H. The pivotal role of VEGF in adipose-derived-stem-cell-mediated regeneration. Expert. Opin. Biol. Ther. 2010. 10(11): 1529-37.

[10]

Хорошилова-Маслова И.П., Илатовская Л.В., Ковальчук Л.В. и др. Регуляция цитокинами постожоговой регенерации рогови- цы в эксперименте. Бюлл. Экспер. Биол. Мед. 1999; 3: 314-16.

[11]

Imanishi J., Kamiyama K., Iguchi I. et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog. Retin. Eye Res. 2000; 19(1): 113-29.

[12]

Siqueira R.C., Voltarelli J.C., Messias A.M. et al. Possible mechanisms of retinal function recovery with the use of cell therapy with bone marrow-derived stem cells. Arq. Bras. Oftalmol. 2010; 73(5): 474-9.

[13]

Torres P.F., Kijlstra A. The role of cytokines in corneal immunopathology. Ocul. Immunol. Inflamm. 2001; 9(1): 9-24.

[14]

Слепова О.С., Герасименко В.А., Макаров В.П. и др. Сравни- тельное исследование роли цитокинов при разных формах глазных заболеваний. Сообщение 1.Фактор некроза опухоли альфа. Вест- ник офтальмологии 1998; 3: 28-32.

[15]

Erdem U., Kerimoglu H., Gundogan F.C. et al. Treatment of Mooren's ulcer with topical administration of interferon alfa 2a. Ophthalmology 2007; 114(3): 446-9.

[16]

Гулиева М.Г. Эффективность Офтальмоферона в комбини- рованном противовирусном лечении тяжелого стромального герпе- тического кератита. Рефрак. Хир. Офтальмол. 2006; 6(4): 48-52.

[17]

Джамбинова Н.С., Гусева М.Р., Сидоренко Е.И. и др. Ци- токинотерапия в регуляции репаративных процессов роговицы (экспериментально-клиническое исследование). Вестник офталь- мологии 2009; 6: 18-21.

[18]

Poon A.C., Geerling G., Dart J.K. et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br. J. Ophthalmol. 2001. 85(10): 1188-97.

[19]

Geremicca W., Fonte C., Vecchio S. Blood components for topical use in tissue regeneration: evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms. Blood Transfus. 2010; 8(2): 107-12.

[20]

Ченцова Е.В. Фетотерапия эндотелиально-эпителиальной дистрофии роговицы. Материалы научно-практической конферен- ции актуальные вопросы офтальмологии; Москва; 2000.

[21]

Kawai T., Akira S. TLR signaling. Semin. Immunol. 2007; 19(1): 24-32.

[22]

Tripathi R.C., Borisuth N.S., Li J. et al. Growth factors in the aqueous humor and their clinical significance. Glaucoma 1994. 3(3): 248-58.

[23]

Hoppenreijs V.P., Pels E., Vrensen G.F. et al. Effects of platelet-derived growth factor on endothelial wound healing of human corneas. Invest. Ophthalmol. Vis. Sci. 1994; 35(1): 150-61.

[24]

Rieck P.W., Gigon M., Jaroszewski J. et al. Increased endothelial survival of organ-cultured corneas stored in FGF-2- supplemented serum-free medium. Invest. Ophthalmol. Vis. Sci. 2003; 44(9): 3826-32.

[25]

Bednarz J., Thalmann-Goetsch A., Richard G. et al. Influence of vascular endothelial growth factor on bovine corneal endothelial cells in a wound-healing model. Ger. J. Ophthalmol. 1996. 5(3): 127-31.

[26]

Шаимова В.А. Роль провопалительных цитокинов при за- болеваниях глаз. Цитокины и воспаление 2005. 4(2): 13-5.

[27]

Saika S. Yin and yang in cytokine regulation of corneal wound healing: roles of TNF-alpha. Cornea 2007. 26(9): S70-74.

[28]

Song J.-S., Lee J.G., Kay E.P. Induction of FGF-2 synthesis by IL-1beta in aqueous humor through P13-kinase and p38 in rabbit corneal endothelium. Invest. Ophthalmol. Vis. Sci. 2010; 51(2): 822-9.

[29]

Joyce N.C., Harris D.L., Mello D.M. Mechanisms of mitotic inhibition in corneal endothelium: contact inhibition and TGF-beta2. Invest. Ophthalmol. Vis. Sci. 2002; 43(7): 2152-9.

[30]

Yamamoto T., Goto H., Yamakawa N. et al. Kinetics of polymorphonuclear leukocytes in an experimental hypopyon model. Exp. Eye Res. 2010; 91(5): 685-90.

RIGHTS & PERMISSIONS

Eco-Vector

AI Summary AI Mindmap
PDF

51

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/